LONGEVA.

Selank: limits of adverse-reaction evidence

Zozulia and colleagues’ abstract compares 30 patients receiving Selank with 32 receiving medazepam. It gives no adverse-event frequencies. [1]

Route and treatment duration are not established from this abstract. It cannot establish an adverse-reaction profile or safety for a particular product or batch; the full report has not been checked. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Adverse events30 patients receiving Selank versus 32 receiving medazepamThe abstract gives no adverse-event frequencies; route and treatment duration are not established from it, so an adverse-reaction profile cannot be determined[1]

References

  1. Zozulia AA et al. (2008). [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia] https://pubmed.ncbi.nlm.nih.gov/18454096/.